A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 01 Apr 2025
At a glance
- Drugs Bempegaldesleukin (Primary) ; CDX 301 (Primary) ; INO 5151 (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Biomarker
- Acronyms PORTER
Most Recent Events
- 24 Mar 2025 According to Vicero media release, Dr. Subudhi was lead principal investigator in this trial.
- 10 Nov 2022 Status changed from active, no longer recruiting to completed.
- 27 Sep 2022 Planned End Date changed from 1 Mar 2023 to 15 Oct 2022.